blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3256216

EP3256216 - MILRINONE COMPOSITION AND METHOD FOR ADMINISTERING SAME [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  04.08.2023
Database last updated on 28.06.2024
FormerGrant of patent is intended
Status updated on  19.03.2023
FormerExamination is in progress
Status updated on  18.11.2022
FormerGrant of patent is intended
Status updated on  17.07.2022
FormerExamination is in progress
Status updated on  02.12.2019
FormerRequest for examination was made
Status updated on  17.11.2017
FormerThe international publication has been made
Status updated on  12.09.2017
Most recent event   Tooltip24.05.2024Lapse of the patent in a contracting state
New state(s): IT		published on 26.06.2024  [2024/26]
Applicant(s)For all designated states
Vanderbilt University
305 Kirkland Hall
2201 West End Avenue
Nashville, TN 37240 / US
For all designated states
Cumberland Pharmaceuticals, Inc.
2525 West End Avenue, Suite 950
Nashville, TN 37203 / US
[2023/36]
Former [2017/51]For all designated states
Vanderbilt University
305 Kirkland Hall
Nashville, TN 37240 / US
For all designated states
Cumberland Pharmaceuticals, Inc.
2525 West End Avenue, Suite 950
Nashville, TN 37203 / US
Inventor(s)01 / HAGLUND, Nicholas A.
2200 W. 47th Place, Apt. 403
Westwood, Kansas 66205 / US
02 / COX, Zachary
313 Goldenrod Court
Nashville, Tennessee 37221 / US
03 / PAVLIV, Leo
707 Walcott Way
Cary, North Carolina 27519 / US
04 / VILA, Andrew
736 Harpeth Bend Drive
Nashville, Tennessee 37221 / US
 [2018/03]
Former [2017/51]01 / HAGLUND, Nicholas A.
231 Cherokee Road
Nashville, Tennessee 37205 / US
02 / COX, Zachary
313 Goldenrod Court
Nashville, Tennessee 37221 / US
03 / PAVLIV, Leo
707 Walcott Way
Cary, North Carolina 27519 / US
04 / VILA, Andrew
736 Harpeth Bend Drive
Nashville, Tennessee 37221 / US
Representative(s)Kransell & Wennborg KB
P.O. Box 27834
115 93 Stockholm / SE
[2017/51]
Application number, filing date16750064.416.02.2016
[2017/51]
WO2016US18055
Priority number, dateUS201562115798P13.02.2015         Original published format: US 201562115798 P
[2017/51]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016131051
Date:18.08.2016
Language:EN
[2016/33]
Type: A1 Application with search report 
No.:EP3256216
Date:20.12.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 18.08.2016 takes the place of the publication of the European patent application.
[2017/51]
Type: B1 Patent specification 
No.:EP3256216
Date:06.09.2023
Language:EN
[2023/36]
Search report(s)International search report - published on:US18.08.2016
(Supplementary) European search report - dispatched on:EP19.07.2018
ClassificationIPC:A61P9/10, A61M11/02, A61K9/12, A61K31/444, A61K47/12
[2022/27]
CPC:
A61K9/0078 (EP,KR,US); A61K31/444 (EP,KR,US); A61K47/12 (EP,US);
A61M11/005 (KR,US); A61M15/0085 (US); A61M16/14 (US);
A61P9/10 (EP); A61M11/00 (EP,US); A61M11/006 (KR);
A61M11/02 (KR); A61M15/00 (EP,US); A61M15/009 (KR) (-)
Former IPC [2018/34]A61P9/10, A61M11/02, A61K9/12
Former IPC [2017/51]A61P9/10, A61M11/02
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/51]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:MILRINONZUSAMMENSETZUNG UND VERFAHREN ZUR VERABREICHUNG DAVON[2017/51]
English:MILRINONE COMPOSITION AND METHOD FOR ADMINISTERING SAME[2017/51]
French:COMPOSITION DE MILRINONE ET SON PROCÉDÉ D'ADMINISTRATION[2017/51]
Entry into regional phase12.09.2017National basic fee paid 
12.09.2017Search fee paid 
12.09.2017Designation fee(s) paid 
12.09.2017Examination fee paid 
Examination procedure12.09.2017Examination requested  [2017/51]
12.09.2017Date on which the examining division has become responsible
07.02.2019Amendment by applicant (claims and/or description)
03.12.2019Despatch of a communication from the examining division (Time limit: M06)
05.06.2020Reply to a communication from the examining division
27.07.2020Despatch of a communication from the examining division (Time limit: M06)
01.02.2021Reply to a communication from the examining division
03.05.2021Despatch of a communication from the examining division (Time limit: M04)
16.07.2021Reply to a communication from the examining division
18.07.2022Communication of intention to grant the patent
17.11.2022Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
20.03.2023Communication of intention to grant the patent
31.07.2023Fee for grant paid
31.07.2023Fee for publishing/printing paid
31.07.2023Receipt of the translation of the claim(s)
Fees paidRenewal fee
27.02.2018Renewal fee patent year 03
27.02.2019Renewal fee patent year 04
27.02.2020Renewal fee patent year 05
25.02.2021Renewal fee patent year 06
25.02.2022Renewal fee patent year 07
27.02.2023Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT06.09.2023
CZ06.09.2023
EE06.09.2023
ES06.09.2023
FI06.09.2023
HR06.09.2023
IT06.09.2023
LT06.09.2023
LV06.09.2023
NL06.09.2023
PL06.09.2023
RO06.09.2023
RS06.09.2023
SE06.09.2023
SK06.09.2023
SM06.09.2023
NO06.12.2023
GR07.12.2023
IS06.01.2024
PT08.01.2024
[2024/26]
Former [2024/25]AT06.09.2023
CZ06.09.2023
EE06.09.2023
ES06.09.2023
FI06.09.2023
HR06.09.2023
LT06.09.2023
LV06.09.2023
NL06.09.2023
PL06.09.2023
RO06.09.2023
RS06.09.2023
SE06.09.2023
SK06.09.2023
SM06.09.2023
NO06.12.2023
GR07.12.2023
IS06.01.2024
PT08.01.2024
Former [2024/23]AT06.09.2023
CZ06.09.2023
EE06.09.2023
ES06.09.2023
FI06.09.2023
HR06.09.2023
LT06.09.2023
LV06.09.2023
NL06.09.2023
RO06.09.2023
RS06.09.2023
SE06.09.2023
SK06.09.2023
SM06.09.2023
NO06.12.2023
GR07.12.2023
IS06.01.2024
PT08.01.2024
Former [2024/20]FI06.09.2023
HR06.09.2023
LT06.09.2023
LV06.09.2023
NL06.09.2023
RS06.09.2023
SE06.09.2023
SM06.09.2023
NO06.12.2023
GR07.12.2023
IS06.01.2024
Former [2024/14]FI06.09.2023
HR06.09.2023
LT06.09.2023
LV06.09.2023
NL06.09.2023
RS06.09.2023
SE06.09.2023
NO06.12.2023
GR07.12.2023
Former [2024/10]FI06.09.2023
HR06.09.2023
LT06.09.2023
LV06.09.2023
RS06.09.2023
SE06.09.2023
NO06.12.2023
GR07.12.2023
Former [2024/09]FI06.09.2023
LT06.09.2023
SE06.09.2023
NO06.12.2023
GR07.12.2023
Former [2024/08]LT06.09.2023
NO06.12.2023
GR07.12.2023
Documents cited:Search[XY]US2005049174  (DENAULT ANDRE [CA]) [X] 13-15 * paragraph [0059] * * paragraph [0075] * * paragraph [0078] * * figure - * * paragraph [0003] - paragraph [0048] * * paragraph [0080] * [Y] 1-12;
 [Y]WO2008005053  (CYDEX INC [US], et al) [Y] 1-12 * claims 1,30,31 * * page 90, line 25 - page 93, line 7 * * example 10 *;
 [I]US7348362  (BANERJEE PARTHA S [US], et al) [I] 1-15 * column 13, line 3 - line 37 * * column 16, line 60 - line 62 * * example 1 ** claim - *
International search[Y]US2005049174  (DENAULT ANDRE [CA]) [Y] 1-12, 13/1-12, 14/13/1-12, 15/13/1-12, 16-17, 28-41 * ; abstract; paragraphs [0059], [0175], [0186] *;
 [Y]US2006030611  (BRISTOW MICHAEL [US], et al) [Y] 30, 33* ; paragraph [0020] *;
 [Y]US2006140873  (CHANG HENG W [US]) [Y] 8-12, 13/8-12, 14/13/1-12, 15/13/8-12, 41 * ; paragraphs [0007]-[0008], [0016], [0018] *;
 [Y]US2011008325  (PIPKIN JAMES D [US], et al) [Y] 1-12, 13/1-12, 14/13/1-12, 15/13/1-12, 16-17, 28-41 * ; abstract; paragraphs [0071], [0074]-[0075], [0078], [0081], [0106], [0109], [0150]-[0152], [0206], [0212], [0220], [0226], [0231], [0272] *
by applicantUS4413127
 US5758637
 US2005049174
 US6983747
 US7059320
 US7322349
    - KIRKLIN JKNAFTEL DCPAGANI FDKORMOS RLSTEVENSON LWBLUME ED et al., "Sixth INTERMACS annual report: A 10,000-patient database", J Heart Lung Transplant, (20140600), vol. 33, no. 6, doi:10.1016/j.healun.2014.04.010, pages 555 - 64, XP029026644

DOI:   http://dx.doi.org/10.1016/j.healun.2014.04.010
    - KORMOS RLTEUTEBERG JJPAGANI FDRUSSELL SDJOHN RMILLER LW et al., "Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: Incidence, risk factors, and effect on outcomes", J Thorac Cardiovasc Surg, (20100500), vol. 139, no. 5, pages 1316 - 24, XP027012337
    - MILLER LWLIETZ K, "Candidate selection for long-term left ventricular assist device therapy for refractory heart failure", J Heart Lung Transplant, (20070700), vol. 25, no. 7, doi:10.1016/j.healun.2006.03.007, pages 756 - 64, XP025015203

DOI:   http://dx.doi.org/10.1016/j.healun.2006.03.007
    - JOHN RPAGANI FDNAKA YBOYLE ACONTE JVRUSSELL SD et al., "Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: Impact of duration of left ventricular assist device support and other variables", J Thorac Cardiovasc Surg, (20100700), vol. 140, no. 1, pages 174 - 81, XP027088885
    - POTAPOV EMEYER DSWAMINATHAN MRAMSAY MEL BANAYOSY ADIEHL C et al., "Inhaled nitric oxide after left ventricular assist device implantation: A prospective, randomized, double-blind, multicenter, placebo-controlled trial", J Heart Lung Transplant, (20110800), vol. 30, no. 8, pages 870 - 8
    - HASENFUSS GTEERLINK JR, "Cardiac inotropes: Current agents and future directions", Eur Heart J, (20110800), vol. 32, no. 15, pages 1838 - 45
    - FELKER GMBENZA RLCHANDLER ABLEIMBERGER JDCUFFE MSCALIFF RM et al., "Heart failure etiology and response to milrinone in decompensated heart failure: Results from the OPTIME-CHF study", J Am Coll Cardiol, (20030319), vol. 41, no. 6, pages 997 - 1003
    - HARALDSSON SAKIELER-JENSEN NRICKSTEN SE, "The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension", Anesth Analg, (20011200), vol. 93, no. 6, page 1439
    - SABLOTZKI ASTARZMANN WSCHEUBEL RGROND SCZESLICK EG, "Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates", Can J Anaesth, (20051200), no. 10, pages 1076 - 82
    - WANG HGONG MZHOU BDAI A, "Comparison of inhaled and intravenous milrinone in patients with pulmonary hypertension undergoing mitral valve surgery", Adv Ther, (20090400), vol. 26, no. 4, doi:10.1007/s12325-009-0019-4, pages 462 - 8, XP037138347

DOI:   http://dx.doi.org/10.1007/s12325-009-0019-4
    - SINGH RCHOUDHURY MSAXENA AKAPOOR PMJUNEJA RKIRAN U, "Inhaled nitroglycerin versus inhaled milrinone in children with congenital heart disease suffering from pulmonary artery hypertension", J Cardiothorac Vasc Anesth, (20101000), vol. 24, no. 5, pages 797 - 801
    - BUCKLEY MSFELDMAN JP, "Nebulized milrinone use in a pulmonary hypertensive crisis", Pharmacotherapy, (20121200), vol. 27, no. 12, pages 1763 - 6
    - FITZPATRICK JR,3RDFREDERICK JRHSU VMKOZIN EDO'HARA MLHOWELL E et al., "Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support", J Heart Lung Transplant, (20081200), vol. 27, no. 12, doi:10.1016/j.healun.2008.09.006, pages 1286 - 92, XP025743953

DOI:   http://dx.doi.org/10.1016/j.healun.2008.09.006
    - NGUYEN AQTHEORET YCHEN CDENAULT AVARIN F, "High performance liquid chromatography using UV detection for the quantification of milrinone in plasma: Improved sensitivity for inhalation", J Chromatogr B Analyt Technol Biomed Life Sci, (20090301), vol. 877, no. 7, doi:10.1016/j.jchromb.2009.01.024, pages 657 - 60, XP025952196

DOI:   http://dx.doi.org/10.1016/j.jchromb.2009.01.024
    - HAGLUND NALUETHGE MDURYEE MHUNTER CALNOUTI YCORCORAN TBECK JMALTAIS SLENIHAN DUM J, Pre-Clinical Testing of Aerosolized Inhaled Milrinone Using a Vibrating Mesh Nebulizer, (20130400), pages S252 - S253
    - MATTHEWS JCKOELLING TMPAGANI FDAARONSON KD, "The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates", J Am Coll Cardiol, (20080603), vol. 51, no. 22, doi:10.1016/j.jacc.2008.03.009, pages 2163 - 72, XP029652132

DOI:   http://dx.doi.org/10.1016/j.jacc.2008.03.009
    - JASKI BEFIFER MAWRIGHT RFBRAUNWALD ECOLUCCI WS, "Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. dose-response relationships and comparison to nitroprusside", J Clin Invest, (19850200), vol. 75, no. 2, pages 643 - 9
    - VAZIR ALEAVER NLYSTER HALEXANIAN AWILTON PBANNER NR, "Is monitoring milrinone therapy useful in advanced heart failure?", Int J Cardiol, (20110616), vol. 149, no. 3, doi:10.1016/j.ijcard.2011.02.068, pages 380 - 1, XP028226769

DOI:   http://dx.doi.org/10.1016/j.ijcard.2011.02.068
    - CHARISOPOULOU DLEAVER NBANNER NR, "Milrinone in advanced heart failure: Dose and therapeutic monitor outside intensive care unit", Angiology, (20140400), vol. 65, no. 4, pages 343 - 9
    - COX ZLCALCUTT MWMORRISON TBAKERS WSDAVIS MBLENIHAN DJ, "Elevation of plasma milrinone concentrations in stage D heart failure associated with renal dysfunction", J Cardiovasc Pharmacol Ther, (20130900), vol. 18, no. 5, pages 433 - 8
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.